Moderna Inc

• Amgen faced intraday downward pressure and profit-taking after rallying to multi-year highs. • Core commercial volume growth remained strong alongside ongoing headwinds from biosimilar competition. • Technical indicators show a neutral MACD of 5.033 and an RSI of 50.194.

• Elevated treasury yields and high valuations caused downward pressure on Vertex shares. • The Crinetics acquisition drove investor focus toward capital deployment and integration efficiency. • Technical indicators show a MACD sell signal and an oversold Williams %R.

• Court ruled for United Therapeutics, confirming patent validity against Liquidia. • Analysts upgraded ratings after the legal victory secured market exclusivity. • The company initiated an accelerated share repurchase to reduce shares.

• McKesson extended its pharmaceutical distribution contract with CVS Health through June 2032. • Management reaffirmed its fiscal 2027 adjusted earnings outlook and long-term growth targets. • The company reported annual revenue of $403.43B and net profit of $4.76B.

• ImmunityBio rallied due to strong commercial momentum for its immunotherapy ANKTIVA. • Wall Street analysts maintain a bullish consensus with an average price target of $12.75. • The company reported $113.29M in annual revenue and a net loss of $351.40M.

• United Therapeutics executed an accelerated share repurchase agreement to complete its buyback program. • The FDA accepted filings for nebulized Tyvaso and ralinepag for regulatory review. • The company reported an annual revenue of $3.18B and net profit of $1.33B.